Chemical Name: NSI-189
CAS No.: 1270138-40-3
Mechanism: Neurogenesis inducer
Status: Phase III
Developer: Neuralstem Inc.
Neuralstem Inc. created the investigational medication NSI-189 to treat neurodegenerative diseases, major depressive disorder, and cognitive impairment. More than 10,000 chemicals were evaluated against NSI-189 to see which ones produced the highest level of neurogenesis in vitro (cellular). NSI-189 will be tested on people with major depressive illness after demonstrating effectiveness in vitro and in rats. will be evaluated in patients with severe depression. By lowering MADRS scores in 220 patients with major depressive disorder, NSI-189 fell short of the Phase II trial's primary goal. Neuropathies, ischemic stroke, and cognitive impairments are among the neurological and central nervous system conditions for which NSI-189 will still be studied.
Neuroregenerative agent
Cognitive enhancement
Mood disorder treatment
Mental health research
Synaptic plasticity
Hippocampal regeneration
Stem cell proliferation
Neurotrophic factors
Neural progenitor cells
Neurocognitive disorders
Memory improvement
Neuroprotective effects
Hippocampus-dependent learning
Central nervous system therapeutics
Novel antidepressant
Non-traditional therapy
Neurobehavioral improvement
Stress-related disorders
Cognitive dysfunction treatment
Biochemical research compound
